)

Caribou Biosciences (CRBU) investor relations material
Caribou Biosciences Citi's Biopharma Back to School Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Technology platform and clinical programs
Chardonnay technology enables highly specific CRISPR genome editing, advancing two off-the-shelf CAR T cell therapies for lymphoma (CB10) and multiple myeloma (CB11), both in phase 1 trials with major data readouts expected by year-end.
CB10 uses PD-1 knockout to prevent CAR T cell exhaustion, aiming for efficacy on par with autologous CAR Ts, with a focus on HLA matching to improve outcomes.
CB11 targets BCMA in myeloma, employing immune cloaking by knocking out HLA class I and overexpressing HLAE to enhance persistence and reduce NK cell rejection.
Both programs leverage a manufacturing platform that allows rapid, scalable production and distribution, with no additional scale-up needed for commercial supply.
The company has paused other programs, prioritizing autoimmune indications for CB10 over AML due to strong oncology data.
Key clinical data and trial design updates
CB10’s phase 1 study includes a 20-patient cohort with ≥4 HLA allele matches, aiming to confirm retrospective findings that higher HLA matching improves outcomes.
Data from this cohort, including response durability and pivotal trial strategy, will be shared at a corporate event before year-end, following FDA discussions.
CB11’s first data release will cover at least 25 patients treated with a higher-dose lymphodepletion protocol, with efficacy benchmarked against bispecifics (60–70% ORR) and plans for dose expansion.
Both programs emphasize the value of off-the-shelf availability, rapid delivery, and potential to expand access beyond academic centers.
International enrollment in the Antler study (CB10) includes sites in Israel and Australia, broadening patient diversity and access.
Commercial and operational strategy
Centralized warehousing and drop-shipping enable community site access without requiring local cryostorage, streamlining logistics for broad adoption.
Thirteen donor lines can cover over 90% of US lymphoma patients with sufficient HLA matching, supporting scalable supply.
Current cash reserves fund operations into 2027, but additional capital will be needed for pivotal trials.
Strategic partnership with Pfizer provides funding, data access, and a right of first negotiation for the myeloma program.
Market research and operational planning are underway to ensure readiness for commercialization, with a vision to expand cell therapy access to underserved patient populations.
Next Caribou Biosciences earnings date

Next Caribou Biosciences earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage